Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
2.245
+0.185 (8.98%)
At close: Oct 6, 2025, 4:00 PM EDT
2.250
+0.005 (0.22%)
After-hours: Oct 6, 2025, 7:46 PM EDT
Immix Biopharma Employees
As of December 31, 2024, Immix Biopharma had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees increased by 4 or 23.53% compared to the previous year.
Employees
21
Change (1Y)
4
Growth (1Y)
23.53%
Revenue / Employee
n/a
Profits / Employee
-$1,101,264
Market Cap
73.33M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 21 | 4 | 23.53% |
Dec 31, 2023 | 17 | 6 | 54.55% |
Dec 31, 2022 | 11 | 9 | 450.00% |
Dec 31, 2021 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMMX News
- 5 days ago - Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 18 days ago - Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 - GlobeNewsWire
- 25 days ago - Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors - GlobeNewsWire
- 4 weeks ago - Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang - GlobeNewsWire
- 6 weeks ago - Immix Biopharma to Present at the Stifel 2025 Healthcare Conference - GlobeNewsWire
- 2 months ago - Immix Biopharma Announces Other Serious Diseases Strategy - GlobeNewsWire
- 3 months ago - Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - GlobeNewsWire
- 3 months ago - Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - GlobeNewsWire